Amol V. Shivange
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Amol V. Shivange has a total of 149 co-authors. Here are the top co-authors by number of shared publications:
- Ulrich Schwaneberg
Institute of Biotechnology RWTH Aachen University Aachen Germany
12 shared publications - Henry A. Lester
California Institute of Technology
5 shared publications - Aaron L. Nichols
California Institute of Technology
4 shared publications Alexander Dennig
Lehrstuhl für Biotechnologie, RWTH Aachen University, Worringerweg 1, D-52074 Aachen, Germany
4 shared publications- Loren L. Looger
HHMI, Department of Neurosciences, University of California, San Diego
4 shared publications - Chengcheng Fan
California Institute of Technology
3 shared publications
Latest Publications
- Open Access
- 15 December 2022
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 11
Correction: Fluorescence activation mechanism and imaging of drug permeation with new sensors for smoking-cessation ligands
Nichols AL, Blumenfeld Z, Fan C, Luebbert L, Blom AEM, Cohen BN, Marvin JS, Borden PM, Kim CH, Muthusamy AK, Shivange AV, Knox HJ, Campello HR, Wang JH, Dougherty DA, Looger LL, Gallagher T, Rees DC, Lester HA. 2022. Fluorescence activation mechanism and imaging of drug permeation with new sensors for smoking-cessation ligands. eLife 11:e74648. doi: 10.7554/eLife.74648.
- 15 December 2022
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 11
Open AccessCorrection: Fluorescence activation mechanism and imaging of drug permeation with new sensors for smoking-cessation ligands
Nichols AL, Blumenfeld Z, Fan C, Luebbert L, Blom AEM, Cohen BN, Marvin JS, Borden PM, Kim CH, Muthusamy AK, Shivange AV, Knox HJ, Campello HR, Wang JH, Dougherty DA, Looger LL, Gallagher T, Rees DC, Lester HA. 2022. Fluorescence activation mechanism and imaging of drug permeation with new sensors for smoking-cessation ligands. eLife 11:e74648. doi: 10.7554/eLife.74648.
- Open Access
- 4 January 2022
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 11
Fluorescence activation mechanism and imaging of drug permeation with new sensors for smoking-cessation ligands
Nicotinic partial agonists provide an accepted aid for smoking cessation and thus contribute to decreasing tobacco-related disease. Improved drugs constitute a continued area of study. However, there remains no reductionist method to examine the cellular and subcellular pharmacokinetic properties of these compounds in living cells. Here, we developed new intensity-based drug-sensing fluorescent reporters (iDrugSnFRs) for the nicotinic partial agonists dianicline, cytisine, and two cytisine derivatives – 10-fluorocytisine and 9-bromo-10-ethylcytisine. We report the first atomic-scale structures of liganded periplasmic binding protein-based biosensors, accelerating development of iDrugSnFRs and also explaining the activation mechanism. The nicotinic iDrugSnFRs detect their drug partners in solution, as well as at the plasma membrane (PM) and in the endoplasmic reticulum (ER) of cell lines and mouse hippocampal neurons. At the PM, the speed of solution changes limits the growth and decay rates of the fluorescence response in almost all cases. In contrast, we found that rates of membrane crossing differ among these nicotinic drugs by >30-fold. The new nicotinic iDrugSnFRs provide insight into the real-time pharmacokinetic properties of nicotinic agonists and provide a methodology whereby iDrugSnFRs can inform both pharmaceutical neuroscience and addiction neuroscience.
- 4 January 2022
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 11
Open AccessFluorescence activation mechanism and imaging of drug permeation with new sensors for smoking-cessation ligands
Nicotinic partial agonists provide an accepted aid for smoking cessation and thus contribute to decreasing tobacco-related disease. Improved drugs constitute a continued area of study. However, there remains no reductionist method to examine the cellular and subcellular pharmacokinetic properties of these compounds in living cells. Here, we developed new intensity-based drug-sensing fluorescent reporters (iDrugSnFRs) for the nicotinic partial agonists dianicline, cytisine, and two cytisine derivatives – 10-fluorocytisine and 9-bromo-10-ethylcytisine. We report the first atomic-scale structures of liganded periplasmic binding protein-based biosensors, accelerating development of iDrugSnFRs and also explaining the activation mechanism. The nicotinic iDrugSnFRs detect their drug partners in solution, as well as at the plasma membrane (PM) and in the endoplasmic reticulum (ER) of cell lines and mouse hippocampal neurons. At the PM, the speed of solution changes limits the growth and decay rates of the fluorescence response in almost all cases. In contrast, we found that rates of membrane crossing differ among these nicotinic drugs by >30-fold. The new nicotinic iDrugSnFRs provide insight into the real-time pharmacokinetic properties of nicotinic agonists and provide a methodology whereby iDrugSnFRs can inform both pharmaceutical neuroscience and addiction neuroscience.
- Open Access
- 8 February 2020
- Published by Cold Spring Harbor Laboratory in bioRxiv
A fast genetically encoded fluorescent sensor for faithfulin vivoacetylcholine detection in mice, fish, worms and flies
Here we design and optimize a genetically encoded fluorescent indicator, iAChSnFR, for the ubiquitous neurotransmitter acetylcholine, based on a bacterial periplasmic binding protein. iAChSnFR shows large fluorescence changes, rapid rise and decay kinetics, and insensitivity to most cholinergic drugs. iAChSnFR revealed large transients in a variety of slice andin vivopreparations in mouse, fish, fly and worm. iAChSnFR will be useful for the study of acetylcholine in all animals.
- 8 February 2020
- Published by Cold Spring Harbor Laboratory in bioRxiv
Open AccessA fast genetically encoded fluorescent sensor for faithfulin vivoacetylcholine detection in mice, fish, worms and flies
Here we design and optimize a genetically encoded fluorescent indicator, iAChSnFR, for the ubiquitous neurotransmitter acetylcholine, based on a bacterial periplasmic binding protein. iAChSnFR shows large fluorescence changes, rapid rise and decay kinetics, and insensitivity to most cholinergic drugs. iAChSnFR revealed large transients in a variety of slice andin vivopreparations in mouse, fish, fly and worm. iAChSnFR will be useful for the study of acetylcholine in all animals.
- 23 July 2019
- Published by Wiley in ChemMedChem
- Vol. 14 (18) , 1620-1632
Structure‐Guided Synthesis and Evaluation of Small‐Molecule Inhibitors Targeting Protein–Protein Interactions of BRCA1 tBRCT Domain
The tandem BRCT domains (tBRCT) of BRCA1 engage phosphoserine‐containing motifs in target proteins to propagate intracellular signals initiated by DNA damage, thereby controlling cell cycle arrest and DNA repair. Recently, we identified Bractoppin, the first small‐molecule inhibitor of the BRCA1 tBRCT domain, which selectively interrupts BRCA1‐mediated cellular responses evoked by DNA damage. Here, we combine structure‐guided chemical elaboration, protein mutagenesis and cellular assays to define the structural features responsible for Bractoppin's activity. Bractoppin fails to bind mutant forms of BRCA1 tBRCT bearing K1702A, a key residue mediating phosphopeptide recognition, or F1662R or L1701K that adjoin the pSer‐recognition site. However, the M1775R mutation, which engages the Phe residue in the consensus phosphopeptide motif pSer‐X‐X‐Phe, does not affect Bractoppin binding, confirming a binding mode distinct from the substrate phosphopeptide binding. We explored these structural features through structure‐guided chemical elaboration and characterized structure–activity relationships (SARs) in biochemical assays. Two analogues, CCBT2088 and CCBT2103 were effective in abrogating BRCA1 foci formation and inhibiting G2 arrest induced by irradiation of cells. Collectively, our findings reveal structural features underlying the activity of a novel inhibitor of phosphopeptide recognition by the BRCA1 tBRCT domain, providing fresh insights to guide the development of inhibitors that target protein–protein interactions.
- 23 July 2019
- Published by Wiley in ChemMedChem
- Vol. 14 (18) , 1620-1632
Structure‐Guided Synthesis and Evaluation of Small‐Molecule Inhibitors Targeting Protein–Protein Interactions of BRCA1 tBRCT Domain
The tandem BRCT domains (tBRCT) of BRCA1 engage phosphoserine‐containing motifs in target proteins to propagate intracellular signals initiated by DNA damage, thereby controlling cell cycle arrest and DNA repair. Recently, we identified Bractoppin, the first small‐molecule inhibitor of the BRCA1 tBRCT domain, which selectively interrupts BRCA1‐mediated cellular responses evoked by DNA damage. Here, we combine structure‐guided chemical elaboration, protein mutagenesis and cellular assays to define the structural features responsible for Bractoppin's activity. Bractoppin fails to bind mutant forms of BRCA1 tBRCT bearing K1702A, a key residue mediating phosphopeptide recognition, or F1662R or L1701K that adjoin the pSer‐recognition site. However, the M1775R mutation, which engages the Phe residue in the consensus phosphopeptide motif pSer‐X‐X‐Phe, does not affect Bractoppin binding, confirming a binding mode distinct from the substrate phosphopeptide binding. We explored these structural features through structure‐guided chemical elaboration and characterized structure–activity relationships (SARs) in biochemical assays. Two analogues, CCBT2088 and CCBT2103 were effective in abrogating BRCA1 foci formation and inhibiting G2 arrest induced by irradiation of cells. Collectively, our findings reveal structural features underlying the activity of a novel inhibitor of phosphopeptide recognition by the BRCA1 tBRCT domain, providing fresh insights to guide the development of inhibitors that target protein–protein interactions.
- Open Access
- 4 February 2019
- Published by Rockefeller University Press in Journal of General Physiology
- Vol. 151 (6) , 738-757
Determining the pharmacokinetics of nicotinic drugs in the endoplasmic reticulum using biosensors
Nicotine dependence is thought to arise in part because nicotine permeates into the endoplasmic reticulum (ER), where it binds to nicotinic receptors (nAChRs) and begins an “inside-out” pathway that leads to up-regulation of nAChRs on the plasma membrane. However, the dynamics of nicotine entry into the ER are unquantified. Here, we develop a family of genetically encoded fluorescent biosensors for nicotine, termed iNicSnFRs. The iNicSnFRs are fusions between two proteins: a circularly permutated GFP and a periplasmic choline-/betaine-binding protein engineered to bind nicotine. The biosensors iNicSnFR3a and iNicSnFR3b respond to nicotine by increasing fluorescence at [nicotine] 75%. Reducing nicotine intake by 10-fold decreases activation to ∼20%. iNicSnFR3a and iNicSnFR3b also sense the smoking cessation drug varenicline, revealing that varenicline also permeates into the ER within seconds. Our iNicSnFRs enable optical subcellular pharmacokinetics for nicotine and varenicline during an early event in the inside-out pathway.
- 4 February 2019
- Published by Rockefeller University Press in Journal of General Physiology
- Vol. 151 (6) , 738-757
Open AccessDetermining the pharmacokinetics of nicotinic drugs in the endoplasmic reticulum using biosensors
Nicotine dependence is thought to arise in part because nicotine permeates into the endoplasmic reticulum (ER), where it binds to nicotinic receptors (nAChRs) and begins an “inside-out” pathway that leads to up-regulation of nAChRs on the plasma membrane. However, the dynamics of nicotine entry into the ER are unquantified. Here, we develop a family of genetically encoded fluorescent biosensors for nicotine, termed iNicSnFRs. The iNicSnFRs are fusions between two proteins: a circularly permutated GFP and a periplasmic choline-/betaine-binding protein engineered to bind nicotine. The biosensors iNicSnFR3a and iNicSnFR3b respond to nicotine by increasing fluorescence at [nicotine] 75%. Reducing nicotine intake by 10-fold decreases activation to ∼20%. iNicSnFR3a and iNicSnFR3b also sense the smoking cessation drug varenicline, revealing that varenicline also permeates into the ER within seconds. Our iNicSnFRs enable optical subcellular pharmacokinetics for nicotine and varenicline during an early event in the inside-out pathway.
- 1 February 2018
- Published by Elsevier in Biophysical Journal
- Vol. 114 (3) , 358a
Microscopy Using Fluorescent Drug Biosensors for “Inside-Out Pharmacology”
- 1 February 2018
- Published by Elsevier in Biophysical Journal
- Vol. 114 (3) , 358a
Microscopy Using Fluorescent Drug Biosensors for “Inside-Out Pharmacology”
- 15 February 2017
- Published by Springer Nature
- p. 145-172
Recent Advances in Directed Phytase Evolution and Rational Phytase Engineering
- 15 February 2017
- Published by Springer Nature
- p. 145-172
Recent Advances in Directed Phytase Evolution and Rational Phytase Engineering
- Open Access
- 1 December 2016
- Published by Taylor & Francis in BioTechniques
- Vol. 61 (6) , 305-314
Protein Consensus-Based Surface Engineering (ProCoS): A Computer-Assisted Method for Directed Protein Evolution
Protein consensus-based surface engineering (ProCoS) is a simple and efficient method for directed protein evolution combining computational analysis and molecular biology tools to engineer protein ...
- 1 December 2016
- Published by Taylor & Francis in BioTechniques
- Vol. 61 (6) , 305-314
Open AccessProtein Consensus-Based Surface Engineering (ProCoS): A Computer-Assisted Method for Directed Protein Evolution
Protein consensus-based surface engineering (ProCoS) is a simple and efficient method for directed protein evolution combining computational analysis and molecular biology tools to engineer protein ...
- 25 September 2015
- Published by Springer Nature in Applied Microbiology and Biotechnology
- Vol. 100 (1) , 227-242
Iterative key-residues interrogation of a phytase with thermostability increasing substitutions identified in directed evolution
Bacterial phytases have attracted industrial interest as animal feed supplement due to their high activity and sufficient thermostability (required for feed pelleting). We devised an approach named KeySIDE, an iterative Key-residues interrogation of the wild type with Substitutions Identified in Directed Evolution for improving Yersinia mollaretii phytase (Ymphytase) thermostability by combining key beneficial substitutions and elucidating their individual roles. Directed evolution yielded in a discovery of nine positions in Ymphytase and combined iteratively to identify key positions. The “best” combination (M6: T77K, Q154H, G187S, and K289Q) resulted in significantly improved thermal resistance; the residual activity improved from 35 % (wild type) to 89 % (M6) at 58 °C and 20-min incubation. Melting temperature increased by 3 °C in M6 without a loss of specific activity. Molecular dynamics simulation studies revealed reduced flexibility in the loops located next to helices (B, F, and K) which possess substitutions (Helix-B: T77K, Helix-F: G187S, and Helix-K: K289E/Q). Reduced flexibility in the loops might be caused by strengthened hydrogen bonding network (e.g., G187S and K289E/K289Q) and a salt bridge (T77K). Our results demonstrate a promising approach to design phytases in food research, and we hope that the KeySIDE might become an attractive approach for understanding of structure–function relationships of enzymes.
- 25 September 2015
- Published by Springer Nature in Applied Microbiology and Biotechnology
- Vol. 100 (1) , 227-242
Iterative key-residues interrogation of a phytase with thermostability increasing substitutions identified in directed evolution
Bacterial phytases have attracted industrial interest as animal feed supplement due to their high activity and sufficient thermostability (required for feed pelleting). We devised an approach named KeySIDE, an iterative Key-residues interrogation of the wild type with Substitutions Identified in Directed Evolution for improving Yersinia mollaretii phytase (Ymphytase) thermostability by combining key beneficial substitutions and elucidating their individual roles. Directed evolution yielded in a discovery of nine positions in Ymphytase and combined iteratively to identify key positions. The “best” combination (M6: T77K, Q154H, G187S, and K289Q) resulted in significantly improved thermal resistance; the residual activity improved from 35 % (wild type) to 89 % (M6) at 58 °C and 20-min incubation. Melting temperature increased by 3 °C in M6 without a loss of specific activity. Molecular dynamics simulation studies revealed reduced flexibility in the loops located next to helices (B, F, and K) which possess substitutions (Helix-B: T77K, Helix-F: G187S, and Helix-K: K289E/Q). Reduced flexibility in the loops might be caused by strengthened hydrogen bonding network (e.g., G187S and K289E/K289Q) and a salt bridge (T77K). Our results demonstrate a promising approach to design phytases in food research, and we hope that the KeySIDE might become an attractive approach for understanding of structure–function relationships of enzymes.